PaxMedica Inc Ordinary Shares PXMD
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.01
- Bid/Ask
- $0.04 / $0.05
- Shares Outstanding
- 126.26M
- Market Cap
- $63,132.19
- Volume/Avg
- 1,500 / 2,554
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 7
- Website
- https://www.paxmedica.com
Valuation
|
Metric
|
PXMD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PXMD
Financial Strength
|
Metric
|
PXMD
|
|---|---|
Quick Ratio | 0.20 |
Current Ratio | 0.36 |
Interest Coverage | — |
Quick Ratio
PXMD
Profitability
|
Metric
|
PXMD
|
|---|---|
Return on Assets (Normalized) | −369.18% |
Return on Equity (Normalized) | −16,581.74% |
Return on Invested Capital (Normalized) | −2,636.40% |
Return on Assets
PXMD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<l<s>n | LOCK|>JGM | $136B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$?@Q$Kd | LOCK|B&H< | $84B | |||
| Moderna Inc
MRNA
| LOCK|t?^$F^y | LOCK|jZ | $81B | |||
| argenx SE ADR
ARGX
| LOCK|M!?cykd | LOCK|Tj | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|X<#tg< | LOCK|L> | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|PJ#Jcp@ | LOCK|jKLK> | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|kNkqX@T | LOCK|Vr<R$ | $28B | |||
| Incyte Corp
INCY
| LOCK|yP!gm?% | LOCK|!& | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|&RMPGBm | LOCK|$%? | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|!T&S@X | LOCK|<% | $14B |
United States